Search Results
Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
global randomized Phase 2 trial (NCT06449209) evaluating pumitamig (also known as BNT327 or BMS986545), an investigational bispecific antibody targeting PD-L1 x VEGF-A, plus chemotherapy in patients with extensive-stage small cell lung cancer ("ES-SCLC"). The data, which are consistent with data presented
More news about: MarketNewsUpdates
Sep 18, 2025, 07:00 ET Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
"As highlighted at recent oral presentations at major scientific conferences, invikafusp has already demonstrated promising single-agent activity in PD-1 resistant tumors including breast cancer," said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. "Advancing
More news about: Marengo Therapeutics
Sep 17, 2025, 13:22 ET Kolmar Korea promove "beleza limpa" com inovações que vão desde embalagens ecológicas até P&D
multimedia:https://www.prnewswire.com/br/comunicados-para-a-imprensa/kolmar-korea-promove-beleza-limpa-com-inovacoes-que-vao-desde-embalagens-ecologicas-ate-pd-302559511.html
More news about: Kolmar Korea
Sep 17, 2025, 12:00 ET LattePanda IOTA Debuts: Palm-sized x86 Single-Board Computer with Intel N150 Delivers Significant Performance Leap
1080@60HzUSB Ports: 3 x USB 3.2 Gen 2 Type A (10Gbps)1 x USB 2.0 Pin Header1x USB Type-C PD 15V (Power Input Only)Network: 1GbE RJ45 Port (Support WOL)Operating System: Windows 10 & 11, ubuntu 22.04 &
More news about: LattePanda
Sep 17, 2025, 09:42 ET Lung Cancer Pioneer Dr. Gilberto Lopes Joins Longevity Company Immorta Bio
principal investigator of KEYNOTE-042, the trial that supported the 2019 FDA first-line approval of pembrolizumab (Keytruda®) in PD-L1–positive advanced NSCLC, broadening access to checkpoint inhibition for hundreds of thousands of patients worldwide since approval. "We
More news about: Immorta Bio Inc.
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy, including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor, and who have no satisfactory alternative treatment
More news about: NetworkNewsWire
Sep 17, 2025, 08:00 ET World's First Portable SSD with Built-in Battery, MOVESPEED PowerDisk, Launches on Kickstarter
external drives. The PowerDisk PD10 eliminates those limits, giving creators a single, streamlined tool that delivers both reliable storage and continuous power. Whether you're filming a wedding, producing a vlog, or traveling the world with your camera, PD10 ensures your story never gets
More news about: MOVESPEED
Sep 17, 2025, 07:00 ET Insightec's Incisionless Focused Ultrasound Therapy Successfully Treats Downton Abbey Creator Lord Julian Fellowes for Essential Tremor
25;5:100101.6 Based on 2023 MedScout claims data on patient population and DBS volumes combined with Insightec treatment data on file (ET and PD).7 Cosgrove et al. Magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremor: 5-year follow-up results.
More news about: Insightec
Sep 16, 2025, 09:00 ET MedRhythms and Edwards Health Care Services, a GEMCORE Family Company, Enter into National Distribution Agreement
partnership enables nationwide access to InTandem® for adults with chronic stroke and MOVIVE™ for people with Parkinson's disease (PD) PORTLAND, Maine, Sept.
More news about: MedRhythms
Sep 16, 2025, 09:00 ET Insightec's Incisionless Focused Ultrasound Therapy Successfully Treats Downton Abbey Creator Lord Julian Fellowes for Essential Tremor
25;5:100101.6 Based on 2023 MedScout claims data on patient population and DBS volumes combined with Insightec treatment data on file (ET and PD).7 Cosgrove et al. Magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremor: 5-year follow-up results.
More news about: Insightec
Sep 16, 2025, 03:35 ET Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
infiltration while reducing immunosuppressive macrophages, thereby boosting sensitivity and efficacy of immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 therapies. Crucially, CX-5461 has not shown marked bone‑marrow suppression at evaluated doses, in contrast to levels commonly seen with
More news about: Senhwa Biosciences, Inc.
Sep 15, 2025, 22:27 ET Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
solid tumors. Two Phase III studies are currently ongoing: one evaluating the combination of ligufalimab and ivonescimab as first-line treatment for PD-L1-positive head and neck squamous cell carcinoma (HNSCC), and another study assessing this combination as first-line therapy for pancreatic cancer.
More news about: Akeso, Inc.
Sep 15, 2025, 20:06 ET The Lustgarten Foundation Announces Landmark Year of Fueling Cutting-Edge Pancreatic Cancer Research
of Oncology at Johns Hopkins University School of Medicine for her study "NC410 and FOLFIRINOX in Combination with Anti-PD-1 with and without Anti-CTLA-4 for Treatment Naive Metastatic Pancreatic Cancer,"
More news about: Lustgarten Foundation
Sep 15, 2025, 17:31 ET Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
Targets of Bispecific Antibodies in Oncology PD-1 × VEGF, PD-1 × CTLA-4, PD-L1 × 4-1BB, TIGIT × PDL1, and others are the prominent targets of bispecific antibodies in NSCLC, whereas targets such as DLL4 × VEGF-A, PD-L1 × VEGF-A, PD-1/IL-2α, Claudin 18.2 (CLDN18.2)/4-1BB, BCMA × CD3, and others
More news about: DelveInsight Business Research, LLP